Irma completes $130 million B round of financing

Yisheng Biopharmaceutical Co.
, Ltd.
(hereinafter referred to as Yisheng Bio) today announced the completion of more than US$130 million in Series B financing.
This round of investment was jointly led by Oceanpine and OrbiMed.
After completing the B round of financing, the company’s institutional investors include: Haisong Capital, Aobo Capital, Straw Capital, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, Heyu Capital, AIHC, Yipu Capital, Superstring Capital , Haitong International, etc.
This round of financing funds will strongly support the construction of the company's R&D center, promote the construction of multiple vaccine products in China and international multi-center clinical trials, as well as the construction of biological vaccine production bases in China and Singapore, and accelerate the process of product commercialization.
In this round of financing, Yikai Capital acted as the company’s exclusive financial advisor; US Wilson Law Firm and Tianyuan Law Firm acted as Esun Bio’s international legal counsel and Chinese legal counsel respectively; Aobo Capital and Adjuvant Capital were provided by Sidley International Lawyers Representative of the firm; Han Kun Law Firm acted as the Chinese legal counsel of Haisong Capital.

，PIKA®，、，、500。YSJA™（™），，1600。PIKA，TLR3、RIG-IMDA5。，，3060。PIKA，，（WHO），（NMPA）， 。YS-ON-001YS-HBV-001.
（YS-SC2-010），YS-HBV-002YS-ON-002，。

CEO：“，PIKA®， ，。 ，，、、。”

As the lead investor of this round, Mr.
Chen Liguang, CEO and managing partner of Haisong Capital, said: “The current new crown epidemic has greatly stimulated the development of the vaccine industry, which is one of Haisong Capital’s key layouts in the medical field.
A biopharmaceutical company focusing on immune regulation technology innovation and vaccine product development.
The founding team has senior industry experience and vaccine research and development and commercialization experience.
The company's listed Yishengjunan rabies vaccine has excellent market performance; at the same time, the company uses The unique PIKA technology platform develops a variety of innovative vaccines related to new adjuvants, which are very competitive.
We are very optimistic about the future development of Essen Bio.
Haisong Capital is very honored to be the lead investor in this round of supporting Essen Bio.
I am delighted to be able to grow with the company and partners.
This financing will help Esen Bio to accelerate its becoming a leading biopharmaceutical company in the world.
"

Wang Ting, Managing Director of Aobo Capital Asia Pacific, said: "China’s biotechnology industry has become increasingly influential in the global innovation wave.
As an old shareholder of EsenBio, we are very pleased to once again participate in supporting EsenBio’s global vaccine and biotechnology The pharmaceutical R&D clinical and industrialization layout, and full of confidence in the executive ability of the management.
"

Zhang Xiao, Managing Director of Ekai Capital, said: "We are honored to support the company's Series B financing.
Vaccines and biopharmaceutical tracks have always been areas of focus for investors, and EsenBio is a scarcity in the field of innovative vaccines and biopharmaceuticals.
The target, the company has won the favor of many well-known institutions with its excellent team, rich pipeline, strong R&D and innovation capabilities.
We believe that the successful completion of this financing will definitely help the company in the'prevention of disease and health care' Achieve new breakthroughs and new leaps along the road.
"

About Yisheng Bio

Yisheng Biopharmaceutical Co.
, Ltd.
is a comprehensive international biopharmaceutical company headquartered in Beijing.
Based on the breakthrough of the new PIKA pickup® immunomodulation technology, it focuses on the research, development and commercialization of antiviral and antitumor innovative vaccines and biological products Operating.
The company has the world's original PIKA vaccine adjuvant platform, and has developed a series of preventive and therapeutic vaccines including rabies, hepatitis B, shingles, influenza, and new crown vaccines.
Esun Bio has more than 500 employees in China, the United States, Singapore and other countries and regions.

About Haisong Capital

It is a professional investment management institution dedicated to long-term investment and value investment.
Focus on investing in high-tech companies and medical companies that can be led by innovative technologies, especially innovative technology companies with breakthroughs and revolutions.
Through long-term and continuous support of outstanding entrepreneurs, supplemented by international operation and management experience and extensive industry resources, it will help enterprises grow rapidly.

About Aobo Capital

Aobo Capital is committed to finding and supporting biomedical and life science companies that can promote human health.
Aobo Capital’s total net assets under management are approximately US$13 billion.
It has been focusing on investments in the global biomedical field for more than 20 years.
The investment projects cover biopharmaceuticals, life sciences, medical devices, medical services and diagnostics.
The investment stages cover the start-up, growth, maturity and post-marketing periods.
The investment team is composed of more than 80 outstanding professionals from all over the world, with professional backgrounds including life sciences, medicine, finance and law.

About Stow Capital

Straw Capital is a global self-owned asset investment institution backed by Fidelity Group.
With its unique capital attributes, Stow Capital can flexibly use funds to support innovative companies to disrupt or lead the market, and help entrepreneurs achieve their ambitions.
At present, the affiliated funds of Stallion and Fidelity Group rank among the top ten in the field of global venture capital.
Our global ecosystem continues to provide invested companies with a huge talent pool and deep local knowledge to help their business development.
Stora has more than 25 years of venture capital experience in China, and has invested in more than 110 companies in the fields of healthcare and technological innovation.
In the past 10 years, we have invested nearly US$6 billion in start-ups worldwide.

About 3W

3W Partners is a private equity investment company focusing on industry integration and growth opportunities.
3W Partners believes that China has entered a new economic situation with slowing growth, traditional overcapacity, globalization, and fierce competition; firmly believes that in this environment, the new generation of industry leaders will be those who can be obtained through industry integration and innovation.
Sustainable entrepreneurs.

About Hillhouse Capital

Hillhouse Capital was established in 2005.
It is a company focused on long-term structural value investment.
After more than ten years of development, it has become one of the largest investment institutions in Asia.
Hillhouse Capital's investment professionals all have rich practical experience in domestic and foreign investment, and can form a perfect combination of capabilities and complementary advantages.
Hillhouse's investment covers TMT, healthcare, consumer retail, corporate services and finance and other fields, and spans all stages of equity investment.

About Adjuvant Capital

It is a life science fund headquartered in New York, USA, aimed at accelerating the development of new technologies to meet the world's most pressing public health challenges.
With the support of well-known investors such as the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation, Adjuvant adopted a team of global scientists and public health experts.
, A network of biopharmaceutical industry veterans and financial professionals to identify investment opportunities.

About Heyu Capital

MSA Capital (MSA Capital) is a private equity investment institution that is deeply involved in China and has a global view.
It has a management scale of approximately US$1.
5 billion.
The funds under entrusted management mainly come from the world's top sovereign wealth funds, international asset management companies, pension funds, and university donations.
Funds, funds of funds, family funds, and well-known Internet and biotechnology entrepreneur leaders in China.

MSA Capital has always focused on in-depth analysis and top-down research, and has rich and profound insights and practices in all aspects of the investment ecosystem.
It has completed about 100 TMT and medical industry investments.
Heyu Capital China is headquartered in Beijing, with permanent teams in the United States, the Middle East and Africa.

About AIHC

An asset management company headquartered in Hong Kong.

About Yipu Capital

Yipu Capital is a cross-border investment fund focusing on the healthcare industry.

About Superstring Capital

Superstring Capital Master Fund LP is an exempted limited partnership in the Cayman Islands and operates as a private equity investment fund.
It focuses on long-term basic investment.
The investment field is listed and unlisted companies in the medical and health field.
Superstring Capital Management LP is responsible management.

About Haitong

Haitong International Securities Group Co.
, Ltd.
("Haitong International", stock code: 665.
HK) is an international financial institution based in Hong Kong and facing the world, committed to becoming a bridge connecting China and overseas capital markets.
The parent company is Haitong Securities Co.
, Ltd.
(stock code: 600837.
SH, 6837.
HK).
Haitong International provides private wealth management, corporate finance, asset management, global markets (mainly including fixed income, foreign exchange and commodities, financial products, prime brokerage, and stock research, and sales) to global and local companies, institutions, retail, and high-net-worth clients.
And trading), investment and other comprehensive financial services.
Haitong International has a robust risk management system that complies with international standards, and has been awarded long-term credit ratings by Moody's Baa2 and Standard & Poor's BBB.
At present, it has built a financial service network covering major global capital markets such as Hong Kong, Singapore, New York, London, Tokyo, Mumbai and Sydney, and is determined to become a world-class Chinese-named, internationally competitive, systemically important and brand influence Investment bank.

Ekai Capital

Established in 2000, Yikai Capital Co.
, Ltd.
is China’s leading investment bank and investment institution focusing on the upgrading and restructuring of the new economy and traditional industries.
Its focus areas include TMT, new consumer and health industries.
There are 19 areas around these three areas.
Segmentation team.

Source: China Esen Biopharmaceutical Co.
, Ltd.